Efsubaglutide Alfa
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2/3 · Active, not recruiting · Enrollment 1003
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Phase IIb:Efsubaglutide Alfa 5 mg QW | n/r | n/r | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 10 mg QW | n/r | n/r | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 20 mg QW | n/r | n/r | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 20 mg Q2W | n/r | n/r | n/r | n/r |
| Phase IIb:Placebo | n/r | n/r | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QW | n/r | n/r | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) High Dose QW | n/r | n/r | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2W | n/r | n/r | n/r | n/r |
| Phase III:Placebo | n/r | n/r | n/r | n/r |
Not shown
- Phase IIb:Efsubaglutide Alfa 5 mg QW: endpoint not reported
- Phase IIb:Efsubaglutide Alfa 10 mg QW: endpoint not reported
- Phase IIb:Efsubaglutide Alfa 20 mg QW: endpoint not reported
- Phase IIb:Efsubaglutide Alfa 20 mg Q2W: endpoint not reported
- Phase IIb:Placebo: endpoint not reported
- Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QW: endpoint not reported
- Phase III:Recommended Phase 3 Dose (RP3D) High Dose QW: endpoint not reported
- Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2W: endpoint not reported
- Phase III:Placebo: endpoint not reported